Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECAR01 (The First Affiliated Hospital of USTC)
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of USTC
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ECAR01 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Anhui Provincial Hospital (also known as the First Affiliated Hospital of the University of Science and Technology of China). This therapy consists of genetically modified T cells that dual-target B-cell maturation antigen (BCMA) and B-lymphocyte antigen CD19. BCMA is a protein primarily expressed on the surface of malignant plasma cells in multiple myeloma, while CD19 is a hallmark biomarker for B-cell lineage cells, including those in acute B-cell leukemia and B-cell lymphoma. By targeting both antigens, ECAR01 is designed to enhance anti-tumor activity and reduce the risk of relapse due to antigen loss or escape. The therapy is currently being evaluated in an early exploratory, dose-escalation clinical study to assess its safety and preliminary efficacy in patients with relapsed or refractory B-cell malignancies.
- Other names
- Anti-BCMA and CD19 CART cellsEnhanced Autologous CAR-T Cell Injection (ECAR01) Targeting CD19 and BCMA
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on ECAR01 (The First Affiliated Hospital of USTC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECAR01 (The First Affiliated Hospital of USTC).